Appointed CEO of Neurotrope in February 2018, Dr. Ryan is an experienced executive with over 20 years of experience in drug development. Prior to joining Neurotrope, he served as CEO of Orthobond, a private company focused on creating proprietary surface modifications to enhance the function of medical devices or pharmaceuticals. Prior still, Dr. Ryan was VP and General Counsel at Cold Spring Harbor Laboratory, a preeminent non-profit institution focused in neuroscience, bioinformatics, cancer, genomics and plant biology. From 2004 until the acquisition by Actavis plc in 2014, Dr. Ryan was SVP Chief Intellectual Property Counsel for Forest Laboratories, a specialty pharmaceutical company in New York. At Forest Laboratories, Dr. Ryan led hundreds of due diligence teams, managed all aspects of patent and trademark litigations, developed cross-functional teams to establish a global IP strategy for dozens of products. Two of the company’s most significant drugs were Lexapro® (for major depressive disorders) and Namenda® (for moderate to severe Alzheimer’s Disease). He began his career in biotechnology with The Collaborative Group, Ltd., a bioscience company providing development, research and manufacturing services to the pharmaceutical and skin care industries.
Dr. Ryan earned his Ph.D. from Stony Brook University, his J.D. from Western New England University, and his B.A. from The College of Wooster.